SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Endocrinol Metab (Seoul). 2020;35(2):425-434.

Effect of Lactobacillus sakei, a Probiotic Derived from Kimchi, on Body Fat in Koreans with Obesity: A Randomized Controlled Study.

, , , ,

제1저자 임수 · 교신저자 임수

소속 (3)
  1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  2. CJ Foods R&D, CJ CheilJedang Corporation, Suwon, Korea.
  3. CJ CheilJedang Corporation, Suwon, Korea.

Abstract

BACKGROUND The increased prevalence of obesity has led to increases in the prevalence of chronic diseases worldwide. There is interest whether probiotics have an effect on obesity, but the effectiveness and safety of only a few probiotics for the treatment of obesity have been reported. The purpose of this study was to investigate whether ingestion of Lactobacillus sakei (CJLS03) derived from kimchi causes weight loss in people with obesity.

METHODS This randomized, double-blind, placebo-controlled, clinical trial involved 114 adults with a body mass index (BMI) ≥25 kg/m2 who were assigned randomly to a CJLS03 or placebo group. The groups received two allocations of either 5×109 colony-forming units of CJLS03/allocation or the equivalent vehicle for 12 weeks. Demographic and biochemical parameters, and body composition including fat and muscle mass were measured at baseline and after 12 weeks. Changes in body fat, weight, and waist circumference were compared between the two treatment groups. Adverse events were monitored during study period.

RESULTS Body fat mass decreased by 0.2 kg in the CJLS03 group and increased by 0.6 kg in the placebo group (0.8 kg difference, P=0.018). After the 12 weeks, waist circumference was 0.8 cm smaller in the CJLS03 group than in the placebo group (P=0.013). BMI and body weight did not change after the 12 weeks. Adverse events were mild and did not differ between the two groups.

CONCLUSION These data suggest that L. sakei (CJLS03) might help people with obesity reduce body fat mass without serious side effects (ClinicalTrials.gov: NCT03248414).

Keywords

Body fatObesityProbioticsLactobacillus sakei

Figures

Fig. 1
Fig. 1 Study design. BIA, bioelectrical impedance analysis; DXA, dual-energy X-ray absorptiometry.
Fig. 2
Fig. 2 Disposition of the study participants during the study period. L. sakei, Lactobacillus sakei.
Fig. 3
Fig. 3 Differences in (A) body weight, (B) body mass index (BMI), (C) body fat, (D) waist circumference, and (E) abdominal visceral fat area between the Lactobacillus sakei (CJLS03) and placebo groups after 6 and 12 weeks. aP<0.05 for L. sakei vs. placebo.

그림 출처: PubMed Central 공개 논문 (PMC7386112)

Conflict of interest statement

CONFLICTS OF INTEREST. This study was supported by a research grant from the CJ Foods R&D, CJ CheilJedang Corporation, Suwon, Korea and by the Korean Endocrine Society of Endocrinology and Metabolism Research Award 2019. The funders had no role in study design, data collection and analysis, or preparation of the manuscript.

그 밖의 정보
출판 형태
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
저널
Endocrinology and metabolism (Seoul, Korea) · eISSN 2093-5978
전자 출판
2020-06-24
MeSH
Adipose Tissue* · Adult · Aged · Body Composition* · Body Mass Index* · Body Weight · Double-Blind Method · Female · Follow-Up Studies · Humans · Latilactobacillus sakei / chemistry · Male · Middle Aged · Obesity / therapy · Probiotics / administration & dosage · Prognosis · Republic of Korea / epidemiology · Weight Loss* · Young Adult
데이터
ClinicalTrials.gov: NCT03248414
참고문헌
37편